Literature DB >> 23775819

Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.

Laurent Sulpice1, Michel Rayar, Mireille Desille, Bruno Turlin, Alain Fautrel, Eveline Boucher, Francisco Llamas-Gutierrez, Bernard Meunier, Karim Boudjema, Bruno Clément, Cédric Coulouarn.   

Abstract

UNLABELLED: Intrahepatic cholangiocarcinoma (ICC) is the second most common type of primary cancer in the liver. ICC is an aggressive cancer with poor prognosis and limited therapeutic strategies. The identification of new drug targets and prognostic biomarkers is an important clinical challenge for ICC. The presence of an abundant stroma is a histological hallmark of ICC. Given the well-established role of the stromal compartment in the progression of cancer diseases, we hypothesized that relevant biomarkers could be identified by analyzing the stroma of ICC. By combining laser capture microdissection and gene expression profiling, we demonstrate that ICC stromal cells exhibit dramatic genomic changes. We identified a signature of 1,073 nonredundant genes that significantly discriminate the tumor stroma from nontumor fibrous tissue. Functional analysis of differentially expressed genes demonstrated that up-regulated genes in the stroma of ICC were related to cell cycle, extracellular matrix, and transforming growth factor beta (TGFβ) pathways. Tissue microarray analysis using an independent cohort of 40 ICC patients validated at a protein level the increased expression of collagen 4A1/COL4A1, laminin gamma 2/LAMC2, osteopontin/SPP1, KIAA0101, and TGFβ2 genes in the stroma of ICC. Statistical analysis of clinical and pathological features demonstrated that the expression of osteopontin, TGFβ2, and laminin in the stroma of ICC was significantly correlated with overall patient survival. More important, multivariate analysis demonstrated that the stromal expression of osteopontin was an independent prognostic marker for overall and disease-free survival.
CONCLUSION: The study identifies clinically relevant genomic alterations in the stroma of ICC, including candidate biomarkers for prognosis, supporting the idea that tumor stroma is an important factor for ICC onset and progression.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775819     DOI: 10.1002/hep.26577

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Sustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes.

Authors:  Emily Hamburg-Shields; Gregg J DiNuoscio; Nathaniel K Mullin; Robert Lafyatis; Radhika P Atit
Journal:  J Pathol       Date:  2015-01-07       Impact factor: 7.996

3.  Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma.

Authors:  Cong-Fa Huang; Guang-Tao Yu; Wei-Ming Wang; Bing Liu; Zhi-Jun Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 4.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

5.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

6.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

7.  Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.

Authors:  Marut Laohaviroj; Yaovalux Chamgramol; Chawalit Pairojkul; Jason Mulvenna; Banchob Sripa
Journal:  Asian Pac J Cancer Prev       Date:  2016

8.  Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Authors:  Kai-Qian Zhou; Wei-Feng Liu; Liu-Xiao Yang; Yun-Fan Sun; Jie Hu; Fei-Yu Chen; Cheng Zhou; Xiang-Yu Zhang; Yuan-Fei Peng; Lei Yu; Jian Zhou; Jia Fan; Zheng Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

9.  Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Cheng Zhou; Mei-Xia Zhang; Yong Yi; Jin-Long Huang; Wei Gan; Juan Zhang; Su-Su Zheng; Bo-Heng Zhang; Shuang-Jian Qiu
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

10.  Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.

Authors:  Robert Montal; Daniela Sia; Carla Montironi; Wei Q Leow; Roger Esteban-Fabró; Roser Pinyol; Miguel Torres-Martin; Laia Bassaganyas; Agrin Moeini; Judit Peix; Laia Cabellos; Miho Maeda; Carlos Villacorta-Martin; Parissa Tabrizian; Leonardo Rodriguez-Carunchio; Giancarlo Castellano; Christine Sempoux; Beatriz Minguez; Timothy M Pawlik; Ismail Labgaa; Lewis R Roberts; Manel Sole; Maria I Fiel; Swan Thung; Josep Fuster; Sasan Roayaie; Augusto Villanueva; Myron Schwartz; Josep M Llovet
Journal:  J Hepatol       Date:  2020-03-12       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.